

# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	17	9.5	178.5	(103.9-285.8)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	2.3	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	11.1	72.0	(31.0-141.9)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.6	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	1.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.6	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	28	37.2	75.3	(50.0-108.8)
Female	0	0.3	nc	(nc-nc)	Female	38	30.8	123.3	(87.2-169.2)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.1	nc	(nc-nc)					
Female	3	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	44.1	63.5	(42.2-91.7)	Male	30	26.8	112.1	(75.6-160.0)
Female	8	15.9	50.3	(21.7-99.2)	Female	24	20.2	118.7	(76.1-176.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	7.2	124.5	(56.8-236.4)	Male	8	8.1	99.1	(42.7-195.3)
Female	5	6.3	78.9	(25.4-184.2)	Female	7	6.7	105.2	(42.1-216.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	21	23.7	88.6	(54.8-135.4)
Female	175	160.2	109.2	(93.6-126.7)	Female	23	20.4	112.6	(71.3-168.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.1	nc	(nc-nc)	Male	13	18.2	71.2	(37.9-121.8)
<b><u>Colon / Rectum</u></b>					Female	7	8.4	83.2	(33.3-171.4)
Male	37	47.0	78.7	(55.4-108.5)	<b><u>Ovary</u></b>				
Female	32	48.1	66.6	(45.5-94.0)	Female	17	14.7	115.7	(67.4-185.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	11.2	nc	(nc-nc)	Male	11	14.6	75.3	(37.5-134.7)
Female	4	3.0	nc	(nc-nc)	Female	17	15.6	108.9	(63.4-174.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	152	144.6	105.1	(89.1-123.2)
Female	1	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	10.0	60.0	(21.9-130.6)
Male	20	21.6	92.4	(56.4-142.7)	Female	8	6.1	131.2	(56.5-258.6)
Female	7	13.0	53.9	(21.6-111.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.5	nc	(nc-nc)
Male	5	6.1	81.9	(26.4-191.2)	<b><u>Thyroid</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	12	9.0	132.8	(68.6-232.1)
<b><u>Leukemia</u></b>					Female	38	26.2	145.3	(102.8-199.4)
Male	19	16.6	114.8	(69.1-179.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	12.1	107.3	(57.1-183.4)	Female	31	36.4	85.1	(57.8-120.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	13.8	36.2	(11.7-84.4)	Male	468	552.0	84.8	(77.3-92.8)
Female	3	4.6	nc	(nc-nc)	Female	515	553.2	93.1	(85.2-101.5)
<b><u>Lung and Bronchus</u></b>									
Male	44	77.9	56.5	(41.0-75.8)					
Female	49	80.1	61.1	(45.2-80.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	12.4	64.5	(27.8-127.2)
Female	0	0.1	nc	(nc-nc)	Female	5	10.7	46.9	(15.1-109.5)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.6	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	8.9	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	5	2.6	189.7	(61.1-442.8)	Female	8	3.7	217.1	(93.5-427.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.8	104.6	(33.7-244.0)
Female	36	29.4	122.6	(85.9-169.7)	Female	4	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	7	9.4	74.6	(29.9-153.7)	<b><u>Ovary</u></b>				
Female	8	7.9	101.2	(43.6-199.4)	Female	4	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	44	30.0	146.7	(106.5-196.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.0	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.1	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.1	nc	(nc-nc)	Female	8	6.9	116.7	(50.3-230.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	106	112.5	94.3	(77.2-114.0)
Female	0	0.8	nc	(nc-nc)	Female	110	98.4	111.8	(91.9-134.8)
<b><u>Lung and Bronchus</u></b>									
Male	8	16.0	50.1	(21.6-98.8)					
Female	6	14.0	42.7	(15.6-93.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Littleton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.5	115.3	(57.5-206.2)	Male	5	6.3	79.3	(25.6-185.1)
Female	1	3.5	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	89.4	(28.8-208.7)
Female	33	40.1	82.3	(56.7-115.6)	Female	5	4.8	105.2	(33.9-245.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.0	nc	(nc-nc)
Male	7	10.8	64.6	(25.9-133.1)	<b><u>Ovary</u></b>				
Female	10	10.9	91.9	(44.0-169.0)	Female	4	3.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	5	3.3	152.2	(49.0-355.2)
Female	0	0.7	nc	(nc-nc)	Female	6	3.4	175.5	(64.1-382.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	33	34.7	95.1	(65.5-133.6)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.3	nc	(nc-nc)
Male	6	5.4	111.9	(40.9-243.5)	Female	0	1.4	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	7.4	95.1	(38.1-196.0)
Male	2	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.9	nc	(nc-nc)	Female	13	8.9	145.5	(77.4-248.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.3	nc	(nc-nc)	Male	118	129.2	91.3	(75.6-109.4)
Female	2	1.1	nc	(nc-nc)	Female	111	132.9	83.5	(68.7-100.6)
<b><u>Lung and Bronchus</u></b>									
Male	18	17.3	104.2	(61.7-164.6)					
Female	10	18.3	54.7	(26.2-100.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	21.9	54.7	(28.2-95.6)	Male	18	13.2	136.2	(80.7-215.3)
Female	9	8.3	108.1	(49.3-205.2)	Female	14	10.3	136.2	(74.4-228.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	10	11.7	85.1	(40.8-156.6)
Female	87	80.1	108.6	(87.0-133.9)	Female	12	10.5	114.1	(58.9-199.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.5	nc	(nc-nc)	Male	5	9.0	55.3	(17.8-129.1)
<b><u>Colon / Rectum</u></b>					Female	1	4.3	nc	(nc-nc)
Male	11	23.3	47.3	(23.6-84.6)	<b><u>Ovary</u></b>				
Female	14	25.3	55.3	(30.2-92.9)	Female	4	7.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.6	nc	(nc-nc)	Male	0	7.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	3	8.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	70	72.5	96.6	(75.3-122.1)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.0	100.8	(32.5-235.2)
Male	10	10.7	93.4	(44.7-171.9)	Female	3	3.2	nc	(nc-nc)
Female	4	6.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	1.7	348.2	(127.2-758.0)
Male	4	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	5	4.4	112.7	(36.3-262.9)
<b><u>Leukemia</u></b>					Female	8	12.9	62.2	(26.8-122.5)
Male	11	8.2	133.6	(66.6-239.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	6.3	79.1	(25.5-184.6)	Female	9	18.2	49.5	(22.6-93.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.8	nc	(nc-nc)	Male	223	274.3	81.3	(71.0-92.7)
Female	4	2.4	nc	(nc-nc)	Female	235	281.8	83.4	(73.1-94.8)
<b><u>Lung and Bronchus</u></b>									
Male	22	38.6	57.0	(35.7-86.4)					
Female	22	40.7	54.1	(33.9-81.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	85	80.9	105.1	(83.9-129.9)	Male	37	56.9	65.1	(45.8-89.7)
Female	41	31.4	130.7	(93.8-177.4)	Female	32	49.9	64.1	(43.8-90.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	18.6	70.0	(37.2-119.7)	Male	19	16.0	119.1	(71.7-185.9)
Female	15	15.8	94.9	(53.1-156.6)	Female	16	13.4	119.2	(68.1-193.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	57	50.6	112.6	(85.3-145.9)
Female	318	355.8	89.4	(79.8-99.8)	Female	33	43.5	75.9	(52.3-106.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	20	13.8	144.7	(88.4-223.5)	Male	52	41.0	126.9	(94.8-166.5)
<b><u>Colon / Rectum</u></b>					Female	12	18.1	66.3	(34.2-115.9)
Male	101	93.7	107.8	(87.8-131.0)	<b><u>Ovary</u></b>				
Female	97	97.8	99.1	(80.4-121.0)	Female	27	32.8	82.3	(54.2-119.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	20	22.5	89.0	(54.4-137.5)	Male	24	28.2	85.2	(54.6-126.8)
Female	5	6.0	83.3	(26.8-194.4)	Female	20	30.6	65.3	(39.9-100.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	11	9.5	115.7	(57.7-207.0)	Male	227	302.9	74.9	(65.5-85.4)
Female	5	7.8	64.2	(20.7-149.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	23	19.5	117.7	(74.6-176.6)
Male	47	48.2	97.6	(71.7-129.8)	Female	20	12.3	162.4	(99.2-250.8)
Female	34	28.2	120.7	(83.6-168.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	13	17.9	72.8	(38.7-124.5)
Male	19	12.5	151.4	(91.1-236.5)	<b><u>Thyroid</u></b>				
Female	8	4.2	189.5	(81.6-373.4)	Male	23	25.0	91.8	(58.2-137.8)
<b><u>Leukemia</u></b>					Female	76	77.0	98.7	(77.7-123.5)
Male	28	35.8	78.3	(52.0-113.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	43	27.5	156.2	(113.0-210.4)	Female	86	79.3	108.5	(86.7-133.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	64	29.5	217.3	(167.3-277.4)	Male	1179	1146.8	102.8	(97.0-108.8)
Female	9	9.6	93.7	(42.8-178.0)	Female	1213	1212.7	100.0	(94.5-105.8)
<b><u>Lung and Bronchus</u></b>									
Male	193	147.9	130.5	(112.7-150.2)					
Female	186	161.9	114.9	(99.0-132.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	25.5	133.2	(92.2-186.1)	Male	16	16.5	97.2	(55.5-157.9)
Female	5	9.5	52.6	(17.0-122.8)	Female	17	12.5	136.3	(79.4-218.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.7	150.5	(60.3-310.1)	Male	2	4.8	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	15	14.5	103.2	(57.7-170.3)
Female	89	96.3	92.4	(74.2-113.8)	Female	9	12.3	73.3	(33.4-139.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.2	nc	(nc-nc)	Male	9	11.5	78.6	(35.9-149.2)
<b><u>Colon / Rectum</u></b>					Female	2	5.0	nc	(nc-nc)
Male	36	28.0	128.7	(90.1-178.2)	<b><u>Ovary</u></b>				
Female	27	28.8	93.7	(61.8-136.4)	Female	8	8.9	90.4	(38.9-178.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	6.8	nc	(nc-nc)	Male	6	8.6	69.5	(25.4-151.4)
Female	3	1.8	nc	(nc-nc)	Female	10	9.3	107.4	(51.4-197.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	84	89.7	93.7	(74.7-116.0)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.9	84.3	(27.2-196.8)
Male	16	13.6	117.6	(67.2-191.1)	Female	2	3.6	nc	(nc-nc)
Female	4	7.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.5	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	16.6	36.2	(13.2-78.7)
Male	8	10.0	80.3	(34.6-158.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.3	82.3	(30.1-179.1)	Female	21	21.8	96.5	(59.7-147.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	8.5	106.4	(48.6-202.1)	Male	311	336.7	92.4	(82.4-103.2)
Female	3	2.8	nc	(nc-nc)	Female	283	333.6	84.8	(75.2-95.3)
<b><u>Lung and Bronchus</u></b>									
Male	28	46.1	60.8	(40.4-87.9)					
Female	35	48.2	72.6	(50.5-100.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	11.5	43.3	(14.0-101.1)	Male	5	7.7	65.0	(21.0-151.8)
Female	4	3.8	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	5	2.3	220.2	(71.0-513.8)
Female	3	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	50	45.3	110.4	(81.9-145.6)	Female	3	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.2	nc	(nc-nc)
Male	15	13.0	115.2	(64.4-190.0)	<b><u>Ovary</u></b>				
Female	14	11.6	121.2	(66.2-203.4)	Female	3	4.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	48	44.6	107.6	(79.3-142.7)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.8	nc	(nc-nc)
Male	2	6.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	8.4	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.0	nc	(nc-nc)	Female	16	10.5	152.1	(86.9-247.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.2	nc	(nc-nc)	Male	152	159.8	95.1	(80.6-111.5)
Female	2	1.2	nc	(nc-nc)	Female	134	148.1	90.5	(75.8-107.1)
<b><u>Lung and Bronchus</u></b>									
Male	24	21.4	112.0	(71.7-166.7)					
Female	13	20.4	63.7	(33.9-109.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	69	77.1	89.5	(69.6-113.2)	Male	42	52.1	80.6	(58.1-109.0)
Female	24	29.6	81.0	(51.9-120.6)	Female	30	45.4	66.1	(44.6-94.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	15	16.4	91.3	(51.0-150.5)	Male	24	14.9	161.4	(103.4-240.2)
Female	17	14.3	119.0	(69.3-190.5)	Female	9	12.7	71.0	(32.4-134.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	54	46.3	116.6	(87.6-152.1)
Female	323	331.3	97.5	(87.2-108.7)	Female	46	40.6	113.4	(83.0-151.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	15	12.4	120.8	(67.5-199.2)	Male	55	36.9	149.2	(112.4-194.2)
<b><u>Colon / Rectum</u></b>					Female	18	16.9	106.6	(63.1-168.4)
Male	111	87.3	127.2	(104.6-153.2)	<b><u>Ovary</u></b>				
Female	113	91.4	123.6	(101.8-148.6)	Female	27	30.5	88.7	(58.4-129.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	27	20.8	129.9	(85.6-188.9)	Male	25	26.4	94.5	(61.2-139.6)
Female	9	5.7	158.1	(72.1-300.1)	Female	25	28.9	86.6	(56.0-127.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	7.8	64.4	(20.7-150.2)	Male	314	277.3	113.2	(101.1-126.5)
Female	3	6.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	18.3	71.1	(37.8-121.5)
Male	35	43.6	80.3	(55.9-111.7)	Female	20	11.5	174.3	(106.4-269.3)
Female	26	26.4	98.6	(64.4-144.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	14.1	77.8	(38.8-139.2)
Male	17	11.5	147.2	(85.7-235.7)	<b><u>Thyroid</u></b>				
Female	4	4.0	nc	(nc-nc)	Male	12	21.6	55.6	(28.7-97.0)
<b><u>Leukemia</u></b>					Female	51	68.2	74.8	(55.7-98.4)
Male	45	32.9	137.0	(99.9-183.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	28	25.2	111.1	(73.8-160.5)	Female	70	74.6	93.8	(73.1-118.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	56	26.9	208.5	(157.5-270.7)	Male	1229	1055.5	116.4	(110.0-123.1)
Female	11	9.0	121.6	(60.6-217.6)	Female	1156	1128.2	102.5	(96.6-108.5)
<b><u>Lung and Bronchus</u></b>									
Male	205	139.3	147.2	(127.7-168.8)					
Female	179	153.9	116.3	(99.9-134.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	15.5	84.1	(44.7-143.8)	Male	23	9.6	239.6	(151.8-359.5)
Female	9	5.4	166.9	(76.2-316.9)	Female	12	7.1	169.1	(87.3-295.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.6	nc	(nc-nc)	Male	5	2.9	174.2	(56.1-406.6)
Female	5	2.2	225.6	(72.7-526.4)	Female	4	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.5	165.3	(90.3-277.4)
Female	56	56.2	99.6	(75.3-129.4)	Female	12	7.0	170.8	(88.2-298.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.9	nc	(nc-nc)
Male	18	16.6	108.3	(64.1-171.1)	<b><u>Ovary</u></b>				
Female	22	16.3	134.7	(84.4-203.9)	Female	9	5.1	176.1	(80.4-334.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	7	5.2	135.0	(54.1-278.1)
Female	0	1.0	nc	(nc-nc)	Female	6	5.3	113.7	(41.5-247.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	57	53.0	107.6	(81.5-139.4)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.5	nc	(nc-nc)
Male	12	7.9	151.7	(78.3-265.1)	Female	2	2.1	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.4	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	9.5	126.7	(65.4-221.4)
Male	10	5.9	170.1	(81.4-312.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.2	144.2	(52.7-313.9)	Female	17	12.7	133.4	(77.7-213.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	5.0	nc	(nc-nc)	Male	211	198.5	106.3	(92.5-121.7)
Female	2	1.6	nc	(nc-nc)	Female	224	191.9	116.7	(101.9-133.0)
<b><u>Lung and Bronchus</u></b>									
Male	22	27.8	79.1	(49.5-119.7)					
Female	27	27.6	97.8	(64.4-142.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	51.6	77.5	(55.4-105.6)	Male	9	35.4	25.4	(11.6-48.3)
Female	32	20.3	158.0	(108.0-223.0)	Female	20	31.7	63.0	(38.5-97.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	10.9	64.2	(25.7-132.3)	Male	5	10.0	49.9	(16.1-116.5)
Female	9	9.6	93.6	(42.7-177.7)	Female	7	8.7	80.7	(32.3-166.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	32	31.2	102.5	(70.1-144.7)
Female	193	227.7	84.8	(73.2-97.6)	Female	20	27.9	71.8	(43.8-110.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	8.9	101.7	(46.4-193.0)	Male	21	24.9	84.4	(52.2-129.1)
<b><u>Colon / Rectum</u></b>					Female	8	11.6	69.1	(29.8-136.2)
Male	71	58.6	121.2	(94.6-152.9)	<b><u>Ovary</u></b>				
Female	80	62.7	127.6	(101.2-158.8)	Female	19	20.9	90.9	(54.7-141.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	20	14.0	143.1	(87.4-221.0)	Male	22	17.7	124.2	(77.8-188.0)
Female	10	3.9	256.7	(122.9-472.1)	Female	19	19.7	96.2	(57.9-150.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	5.4	93.3	(30.1-217.8)	Male	135	186.2	72.5	(60.8-85.8)
Female	3	4.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	12.3	130.3	(74.4-211.5)
Male	35	29.5	118.5	(82.5-164.8)	Female	6	7.9	76.3	(27.9-166.1)
Female	18	18.0	99.8	(59.1-157.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	10.2	88.2	(40.2-167.4)
Male	11	7.8	141.4	(70.5-253.0)	<b><u>Thyroid</u></b>				
Female	6	2.7	219.6	(80.2-478.0)	Male	17	15.0	113.7	(66.2-182.0)
<b><u>Leukemia</u></b>					Female	51	48.4	105.3	(78.4-138.5)
Male	23	21.7	106.0	(67.2-159.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	17.0	99.9	(58.2-159.9)	Female	56	51.1	109.7	(82.8-142.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	24	18.0	133.1	(85.2-198.0)	Male	671	710.1	94.5	(87.5-101.9)
Female	8	6.2	129.6	(55.8-255.4)	Female	778	775.6	100.3	(93.4-107.6)
<b><u>Lung and Bronchus</u></b>									
Male	122	93.8	130.1	(108.0-155.4)					
Female	114	105.2	108.4	(89.4-130.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	7.5	67.0	(21.6-156.3)	Male	16	4.6	347.2	(198.3-563.9)
Female	2	2.6	nc	(nc-nc)	Female	7	3.4	203.8	(81.7-420.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	37	28.0	132.1	(93.0-182.0)	Female	2	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.4	nc	(nc-nc)
Male	6	7.9	75.6	(27.6-164.5)	<b><u>Ovary</u></b>				
Female	3	7.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	35	26.7	131.0	(91.2-182.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	4.5	199.0	(90.8-377.8)
Male	2	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	5	6.6	76.0	(24.5-177.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	100	96.7	103.4	(84.1-125.8)
Female	0	0.8	nc	(nc-nc)	Female	101	94.3	107.1	(87.3-130.2)
<b><u>Lung and Bronchus</u></b>									
Male	7	13.6	51.4	(20.6-105.8)					
Female	9	14.0	64.4	(29.4-122.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	16.9	106.7	(63.2-168.6)	Male	22	12.5	175.6	(110.0-265.8)
Female	1	6.0	nc	(nc-nc)	Female	18	10.7	167.7	(99.4-265.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.2	120.0	(38.7-280.1)	Male	3	3.5	nc	(nc-nc)
Female	8	3.4	238.2	(102.6-469.5)	Female	1	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.6	nc	(nc-nc)	Male	12	11.2	107.5	(55.5-187.8)
Female	88	82.8	106.3	(85.3-131.0)	Female	3	9.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.3	nc	(nc-nc)	Male	11	9.7	113.4	(56.5-202.9)
<b><u>Colon / Rectum</u></b>					Female	2	3.9	nc	(nc-nc)
Male	27	20.9	129.0	(85.0-187.7)	<b><u>Ovary</u></b>				
Female	27	19.8	136.1	(89.7-198.1)	Female	9	7.2	124.5	(56.8-236.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	8	5.8	136.9	(59.0-269.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	60	67.6	88.8	(67.7-114.2)
Female	3	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.3	140.3	(51.2-305.4)
Male	13	11.1	117.2	(62.3-200.4)	Female	2	2.4	nc	(nc-nc)
Female	8	6.1	132.0	(56.8-260.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.4	177.8	(64.9-386.9)
Male	0	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	15	5.8	258.7	(144.7-426.7)
<b><u>Leukemia</u></b>					Female	19	18.0	105.7	(63.6-165.1)
Male	8	7.7	104.1	(44.8-205.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	5.5	144.4	(62.2-284.5)	Female	10	17.9	55.8	(26.7-102.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.8	nc	(nc-nc)	Male	270	251.8	107.2	(94.8-120.8)
Female	3	2.0	nc	(nc-nc)	Female	285	261.5	109.0	(96.7-122.4)
<b><u>Lung and Bronchus</u></b>									
Male	30	31.3	95.8	(64.6-136.7)					
Female	41	32.3	127.0	(91.1-172.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	25.5	78.6	(48.0-121.4)	Male	40	16.0	249.2	(178.0-339.4)
Female	13	9.1	142.1	(75.6-243.0)	Female	24	12.6	190.8	(122.2-283.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	7	4.8	145.4	(58.3-299.6)
Female	6	3.9	152.8	(55.8-332.6)	Female	7	3.9	177.9	(71.3-366.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.1	113.2	(64.7-183.8)
Female	128	101.2	126.5	(105.5-150.4)	Female	15	12.2	122.5	(68.5-202.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	12	11.5	104.0	(53.7-181.6)
<b><u>Colon / Rectum</u></b>					Female	5	5.2	96.8	(31.2-226.0)
Male	26	27.7	93.9	(61.3-137.6)	<b><u>Ovary</u></b>				
Female	18	27.6	65.2	(38.6-103.0)	Female	10	9.2	109.1	(52.2-200.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	6.9	nc	(nc-nc)	Male	13	8.7	149.4	(79.5-255.5)
Female	1	1.8	nc	(nc-nc)	Female	12	8.9	135.0	(69.7-235.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	103	93.8	109.8	(89.6-133.2)
Female	0	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.9	101.4	(37.0-220.7)
Male	11	13.6	81.0	(40.4-144.9)	Female	2	3.5	nc	(nc-nc)
Female	7	8.0	87.6	(35.1-180.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.2	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	8	5.8	138.2	(59.5-272.4)
<b><u>Leukemia</u></b>					Female	17	17.3	98.4	(57.3-157.5)
Male	15	9.8	153.8	(86.0-253.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	7.1	126.3	(57.6-239.8)	Female	16	23.6	67.8	(38.7-110.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	8.6	58.3	(18.8-136.0)	Male	357	337.2	105.9	(95.2-117.4)
Female	4	2.8	nc	(nc-nc)	Female	377	338.5	111.4	(100.4-123.2)
<b><u>Lung and Bronchus</u></b>									
Male	34	46.4	73.3	(50.8-102.5)					
Female	43	48.1	89.4	(64.7-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.4	95.2	(38.1-196.2)	Male	5	4.4	112.6	(36.3-262.7)
Female	4	2.8	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	3.9	205.1	(88.3-404.1)
Female	33	26.7	123.6	(85.0-173.6)	Female	3	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.4	nc	(nc-nc)
Male	5	7.8	64.3	(20.7-150.1)	<b><u>Ovary</u></b>				
Female	8	8.2	97.6	(42.0-192.3)	Female	2	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	28	25.0	112.1	(74.5-162.1)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.2	120.3	(38.8-280.7)
Male	8	2.7	294.3	(126.7-579.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	5	6.2	80.8	(26.1-188.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	91	92.7	98.2	(79.0-120.5)
Female	0	0.8	nc	(nc-nc)	Female	98	93.6	104.7	(85.0-127.6)
<b><u>Lung and Bronchus</u></b>									
Male	4	13.1	nc	(nc-nc)					
Female	17	13.9	122.2	(71.2-195.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	35.6	95.6	(66.2-133.6)	Male	22	24.4	90.3	(56.6-136.8)
Female	11	14.1	78.3	(39.0-140.0)	Female	16	20.7	77.2	(44.1-125.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	7.4	94.1	(37.7-194.0)	Male	8	6.9	115.3	(49.6-227.2)
Female	5	6.4	78.7	(25.4-183.6)	Female	6	6.0	100.8	(36.8-219.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	22	21.5	102.2	(64.0-154.7)
Female	137	153.1	89.5	(75.1-105.8)	Female	17	18.9	90.0	(52.4-144.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.7	158.0	(72.1-300.0)	Male	16	17.4	91.7	(52.4-149.0)
<b><u>Colon / Rectum</u></b>					Female	15	7.8	191.9	(107.3-316.5)
Male	47	40.8	115.2	(84.7-153.2)	<b><u>Ovary</u></b>				
Female	58	43.6	133.1	(101.1-172.1)	Female	16	14.0	114.4	(65.4-185.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	9.7	123.5	(63.8-215.8)	Male	9	12.3	73.3	(33.4-139.1)
Female	3	2.7	nc	(nc-nc)	Female	11	13.7	80.0	(39.9-143.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	3.5	173.1	(63.2-376.8)	Male	128	129.8	98.6	(82.3-117.3)
Female	2	2.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	8.5	105.6	(48.2-200.5)
Male	30	20.6	146.0	(98.5-208.4)	Female	5	5.5	90.7	(29.2-211.7)
Female	9	12.2	74.1	(33.8-140.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	6.4	78.4	(25.3-182.9)
Male	6	5.4	111.0	(40.5-241.7)	<b><u>Thyroid</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	9	10.2	88.0	(40.1-167.0)
<b><u>Leukemia</u></b>					Female	40	30.6	130.8	(93.4-178.1)
Male	19	14.9	127.7	(76.8-199.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	11.6	94.8	(47.2-169.6)	Female	37	33.9	109.1	(76.8-150.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	12.6	103.4	(55.0-176.8)	Male	493	491.0	100.4	(91.7-109.7)
Female	6	4.2	143.4	(52.4-312.1)	Female	533	522.5	102.0	(93.5-111.0)
<b><u>Lung and Bronchus</u></b>									
Male	51	64.6	79.0	(58.8-103.9)					
Female	67	71.3	93.9	(72.8-119.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	26.6	86.4	(54.8-129.7)	Male	39	18.0	217.0	(154.3-296.7)
Female	12	9.3	129.4	(66.8-226.0)	Female	27	14.1	191.1	(125.9-278.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.3	132.0	(52.9-271.9)	Male	7	5.3	132.2	(53.0-272.3)
Female	7	4.4	158.4	(63.5-326.5)	Female	2	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	11	15.7	69.8	(34.8-125.0)
Female	142	113.1	125.6	(105.8-148.0)	Female	11	13.0	84.5	(42.1-151.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.9	127.4	(41.1-297.3)	Male	10	13.5	74.0	(35.4-136.1)
<b><u>Colon / Rectum</u></b>					Female	5	5.6	89.7	(28.9-209.3)
Male	34	30.3	112.2	(77.7-156.8)	<b><u>Ovary</u></b>				
Female	32	28.2	113.4	(77.5-160.1)	Female	12	10.1	118.6	(61.2-207.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.7	nc	(nc-nc)	Male	13	9.4	138.7	(73.8-237.2)
Female	2	1.8	nc	(nc-nc)	Female	7	8.9	78.5	(31.4-161.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	122	106.8	114.2	(94.9-136.4)
Female	2	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.4	nc	(nc-nc)
Male	25	15.7	159.1	(103.0-234.9)	Female	4	3.5	nc	(nc-nc)
Female	6	8.7	68.9	(25.2-150.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.3	nc	(nc-nc)
Male	0	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	7	7.2	97.3	(39.0-200.4)
<b><u>Leukemia</u></b>					Female	26	21.0	123.9	(80.9-181.5)
Male	9	10.7	83.8	(38.3-159.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	7.6	nc	(nc-nc)	Female	27	26.4	102.4	(67.5-149.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	9.9	101.1	(48.4-185.9)	Male	403	376.1	107.2	(97.0-118.2)
Female	1	3.0	nc	(nc-nc)	Female	431	368.0	117.1	(106.3-128.7)
<b><u>Lung and Bronchus</u></b>									
Male	49	50.0	98.0	(72.5-129.6)					
Female	69	50.9	135.6	(105.5-171.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	22.7	136.3	(92.6-193.4)	Male	22	13.4	164.4	(103.0-248.9)
Female	9	8.3	108.7	(49.6-206.4)	Female	15	10.1	148.0	(82.8-244.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	6	4.1	146.8	(53.6-319.6)
Female	2	3.1	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	17	11.7	144.9	(84.4-232.1)
Female	86	80.3	107.1	(85.7-132.3)	Female	14	10.5	133.4	(72.9-223.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	13	8.7	149.9	(79.8-256.4)
<b><u>Colon / Rectum</u></b>					Female	5	4.3	117.3	(37.8-273.8)
Male	19	23.1	82.1	(49.4-128.3)	<b><u>Ovary</u></b>				
Female	28	24.0	116.6	(77.5-168.5)	Female	9	7.4	121.7	(55.5-231.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.7	105.7	(38.6-230.2)	Male	8	7.4	108.0	(46.5-212.8)
Female	0	1.6	nc	(nc-nc)	Female	8	8.0	99.8	(43.0-196.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	82	73.9	110.9	(88.2-137.7)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.0	99.5	(32.1-232.2)
Male	11	10.7	103.1	(51.4-184.5)	Female	1	3.0	nc	(nc-nc)
Female	8	6.7	118.7	(51.1-234.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.7	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	4	1.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	12.5	88.3	(44.0-158.0)
Male	7	8.1	85.9	(34.4-177.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	6.1	164.9	(78.9-303.2)	Female	14	18.7	74.7	(40.8-125.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.7	nc	(nc-nc)	Male	297	278.3	106.7	(94.9-119.6)
Female	2	2.4	nc	(nc-nc)	Female	310	281.7	110.0	(98.1-123.0)
<b><u>Lung and Bronchus</u></b>									
Male	31	40.8	75.9	(51.6-107.8)					
Female	59	43.6	135.3	(103.0-174.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.2	119.1	(59.4-213.2)	Male	6	5.7	105.9	(38.7-230.6)
Female	3	3.0	nc	(nc-nc)	Female	6	4.0	149.8	(54.7-326.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	38	32.5	116.8	(82.6-160.3)	Female	5	4.0	124.6	(40.2-290.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	11	4.0	276.7	(137.9-495.1)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	6	9.8	61.1	(22.3-133.1)	<b><u>Ovary</u></b>				
Female	11	8.9	123.1	(61.4-220.4)	Female	5	3.0	168.8	(54.4-393.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	46	33.1	139.2	(101.9-185.6)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.1	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	5.3	94.4	(30.4-220.3)
Male	4	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	11	7.7	143.2	(71.4-256.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	128	119.3	107.3	(89.5-127.5)
Female	1	0.9	nc	(nc-nc)	Female	113	109.9	102.8	(84.8-123.6)
<b><u>Lung and Bronchus</u></b>									
Male	15	16.7	89.6	(50.1-147.9)					
Female	12	16.3	73.7	(38.1-128.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	9.9	101.2	(48.4-186.1)	Male	4	6.7	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	7	5.8	121.2	(48.6-249.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.9	118.1	(47.3-243.3)
Female	46	44.4	103.7	(75.9-138.3)	Female	3	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.2	nc	(nc-nc)
Male	20	11.3	176.3	(107.6-272.3)	<b><u>Ovary</u></b>				
Female	18	11.7	154.0	(91.2-243.5)	Female	2	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	36	37.3	96.6	(67.6-133.7)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	5	3.4	144.9	(46.7-338.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.7	114.9	(55.0-211.3)
Male	3	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.1	nc	(nc-nc)	Female	8	10.0	79.7	(34.3-157.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	132	137.4	96.1	(80.4-114.0)
Female	2	1.2	nc	(nc-nc)	Female	150	146.9	102.1	(86.4-119.8)
<b><u>Lung and Bronchus</u></b>									
Male	12	18.2	66.1	(34.1-115.5)					
Female	20	19.9	100.3	(61.2-154.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	11.6	77.5	(35.3-147.0)	Male	9	7.9	113.4	(51.8-215.4)
Female	6	4.0	150.2	(54.8-326.9)	Female	9	6.2	144.9	(66.1-275.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	5	2.3	215.0	(69.3-501.7)
Female	4	2.0	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.0	85.2	(31.1-185.5)
Female	49	50.1	97.8	(72.3-129.3)	Female	3	5.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	7	6.0	116.1	(46.5-239.2)
<b><u>Colon / Rectum</u></b>					Female	1	2.4	nc	(nc-nc)
Male	18	13.6	132.0	(78.2-208.7)	<b><u>Ovary</u></b>				
Female	16	12.6	126.5	(72.3-205.5)	Female	5	4.4	112.5	(36.2-262.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	3.3	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	60	44.9	133.7	(102.0-172.1)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.8	nc	(nc-nc)
Male	6	6.9	86.7	(31.7-188.7)	Female	1	1.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.4	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	9.5	95.0	(43.4-180.4)
Male	6	4.8	124.7	(45.5-271.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	3.4	207.0	(82.9-426.6)	Female	10	11.2	88.9	(42.6-163.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.4	nc	(nc-nc)	Male	164	163.6	100.2	(85.5-116.8)
Female	1	1.3	nc	(nc-nc)	Female	150	161.1	93.1	(78.8-109.2)
<b><u>Lung and Bronchus</u></b>									
Male	12	21.5	55.9	(28.8-97.6)					
Female	12	21.3	56.2	(29.0-98.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	65	60.4	107.6	(83.0-137.1)	Male	29	38.4	75.6	(50.6-108.6)
Female	22	24.3	90.7	(56.8-137.3)	Female	23	33.3	69.1	(43.8-103.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	11.0	127.8	(69.8-214.4)	Male	8	11.1	72.1	(31.0-142.0)
Female	11	10.1	109.0	(54.3-195.0)	Female	12	10.1	118.8	(61.3-207.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	29	34.0	85.3	(57.1-122.4)
Female	235	240.1	97.9	(85.8-111.2)	Female	22	31.5	69.9	(43.8-105.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	8.5	105.3	(48.1-199.9)	Male	36	25.5	141.0	(98.7-195.2)
<b><u>Colon / Rectum</u></b>					Female	13	12.8	101.7	(54.1-174.0)
Male	75	65.2	115.1	(90.5-144.3)	<b><u>Ovary</u></b>				
Female	81	73.7	109.8	(87.2-136.5)	Female	27	22.4	120.3	(79.2-175.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	15.2	78.8	(40.7-137.6)	Male	19	20.0	94.9	(57.1-148.2)
Female	5	4.6	108.5	(35.0-253.3)	Female	11	23.8	46.2	(23.0-82.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	5.2	116.1	(42.4-252.6)	Male	157	196.2	80.0	(68.0-93.6)
Female	4	4.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	13.8	101.3	(55.3-170.0)
Male	31	30.6	101.3	(68.8-143.8)	Female	10	9.4	106.6	(51.0-196.1)
Female	25	19.8	126.5	(81.8-186.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	9.4	116.5	(58.1-208.5)
Male	13	8.4	155.6	(82.7-266.0)	<b><u>Thyroid</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	9	14.5	62.1	(28.3-117.9)
<b><u>Leukemia</u></b>					Female	47	46.0	102.1	(75.0-135.8)
Male	26	23.8	109.3	(71.4-160.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	25	19.1	130.9	(84.7-193.3)	Female	60	53.8	111.4	(85.0-143.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	19.0	89.4	(52.0-143.1)	Male	741	771.8	96.0	(89.2-103.2)
Female	8	7.0	114.1	(49.1-224.8)	Female	852	850.3	100.2	(93.6-107.2)
<b><u>Lung and Bronchus</u></b>									
Male	110	106.3	103.5	(85.0-124.7)					
Female	124	121.4	102.1	(84.9-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	10.9	137.2	(76.7-226.3)	Male	6	7.7	77.4	(28.3-168.6)
Female	2	4.2	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	13	6.9	188.8	(100.4-322.9)
Female	47	51.6	91.1	(66.9-121.1)	Female	7	5.9	119.2	(47.7-245.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.5	nc	(nc-nc)
Male	19	13.1	145.3	(87.5-227.0)	<b><u>Ovary</u></b>				
Female	14	13.4	104.1	(56.9-174.7)	Female	7	4.6	153.2	(61.4-315.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.2	221.8	(88.9-457.1)	Male	2	3.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	44	42.8	102.9	(74.8-138.1)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.7	nc	(nc-nc)
Male	4	6.8	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	0	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.7	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	10.2	117.6	(60.7-205.4)
Male	2	4.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.6	nc	(nc-nc)	Female	8	11.3	70.7	(30.4-139.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.2	nc	(nc-nc)	Male	164	157.6	104.1	(88.7-121.3)
Female	0	1.3	nc	(nc-nc)	Female	152	167.6	90.7	(76.9-106.3)
<b><u>Lung and Bronchus</u></b>									
Male	19	20.3	93.7	(56.4-146.4)					
Female	28	21.9	128.1	(85.1-185.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	29.9	80.3	(51.5-119.5)	Male	23	19.3	119.0	(75.4-178.5)
Female	17	12.3	138.6	(80.7-222.0)	Female	19	16.7	113.8	(68.5-177.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	5.5	180.6	(86.4-332.1)	Male	4	5.7	nc	(nc-nc)
Female	7	5.2	135.7	(54.4-279.6)	Female	2	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	22	17.0	129.1	(80.9-195.5)
Female	132	127.0	104.0	(87.0-123.3)	Female	16	16.1	99.5	(56.9-161.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.4	nc	(nc-nc)	Male	17	13.6	125.0	(72.8-200.1)
<b><u>Colon / Rectum</u></b>					Female	5	6.6	75.5	(24.3-176.1)
Male	44	32.9	133.7	(97.1-179.5)	<b><u>Ovary</u></b>				
Female	34	37.3	91.1	(63.1-127.3)	Female	13	11.6	111.7	(59.4-191.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	8.0	125.5	(60.1-230.8)	Male	11	10.2	108.3	(54.0-193.7)
Female	1	2.3	nc	(nc-nc)	Female	16	12.0	133.2	(76.1-216.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	95	106.3	89.4	(72.3-109.3)
Female	1	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	7.0	86.1	(31.4-187.3)
Male	16	16.1	99.2	(56.6-161.1)	Female	5	4.7	106.0	(34.2-247.3)
Female	9	10.3	87.7	(40.0-166.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	3.8	nc	(nc-nc)
Male	10	4.4	227.7	(109.0-418.8)	<b><u>Thyroid</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	12	7.4	162.7	(84.0-284.3)
<b><u>Leukemia</u></b>					Female	27	23.1	117.0	(77.1-170.3)
Male	20	11.8	169.6	(103.6-262.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	9.7	62.2	(22.7-135.3)	Female	32	28.8	111.3	(76.1-157.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	10.0	49.9	(16.1-116.5)	Male	418	396.3	105.5	(95.6-116.1)
Female	2	3.6	nc	(nc-nc)	Female	431	438.3	98.3	(89.3-108.1)
<b><u>Lung and Bronchus</u></b>									
Male	54	53.9	100.2	(75.3-130.7)					
Female	50	62.2	80.4	(59.7-106.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	24	23.2	103.2	(66.1-153.6)	Female	7	2.5	277.5	(111.2-571.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	2	6.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	5.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	27	22.1	122.2	(80.5-177.8)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.3	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.7	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.5	nc	(nc-nc)	Female	5	5.2	96.4	(31.1-224.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	60	79.1	75.9	(57.9-97.7)
Female	1	0.6	nc	(nc-nc)	Female	71	73.3	96.9	(75.6-122.2)
<b><u>Lung and Bronchus</u></b>									
Male	4	10.2	nc	(nc-nc)					
Female	7	9.5	73.8	(29.6-152.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.7	74.9	(24.2-174.9)	Male	5	4.5	111.4	(35.9-259.9)
Female	2	2.4	nc	(nc-nc)	Female	5	3.6	139.3	(44.9-325.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	24	28.8	83.3	(53.4-124.0)	Female	2	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.4	nc	(nc-nc)
Male	8	7.6	105.0	(45.2-207.0)	<b><u>Ovary</u></b>				
Female	6	7.4	81.5	(29.8-177.3)	Female	5	2.6	195.8	(63.1-456.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	25	25.5	97.9	(63.3-144.5)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.6	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.8	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.4	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	88	92.7	95.0	(76.2-117.0)
Female	2	0.7	nc	(nc-nc)	Female	86	93.6	91.9	(73.5-113.5)
<b><u>Lung and Bronchus</u></b>									
Male	14	12.4	113.0	(61.7-189.5)					
Female	16	12.8	124.8	(71.3-202.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	47.7	113.2	(85.0-147.7)	Male	25	31.1	80.4	(52.0-118.8)
Female	25	18.9	132.1	(85.5-195.0)	Female	27	26.8	100.8	(66.4-146.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	9.2	87.0	(37.5-171.5)	Male	11	9.0	121.7	(60.7-217.7)
Female	9	8.3	108.0	(49.3-205.0)	Female	5	8.0	62.5	(20.1-145.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	27	27.6	97.8	(64.4-142.3)
Female	197	201.1	98.0	(84.8-112.6)	Female	27	25.2	107.3	(70.7-156.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	7.2	111.8	(48.1-220.2)	Male	18	21.9	82.1	(48.7-129.8)
<b><u>Colon / Rectum</u></b>					Female	8	10.4	76.9	(33.1-151.5)
Male	56	53.1	105.4	(79.6-136.9)	<b><u>Ovary</u></b>				
Female	52	58.4	89.1	(66.5-116.8)	Female	10	18.5	54.2	(25.9-99.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	12.6	95.1	(49.1-166.1)	Male	19	16.2	117.2	(70.5-183.0)
Female	1	3.6	nc	(nc-nc)	Female	17	18.6	91.5	(53.3-146.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	4.0	nc	(nc-nc)	Male	186	166.9	111.4	(96.0-128.7)
Female	3	3.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	11.2	116.3	(61.9-198.9)
Male	27	25.8	104.8	(69.0-152.4)	Female	7	7.4	94.9	(38.0-195.5)
Female	16	16.1	99.5	(56.9-161.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	6.7	163.0	(81.3-291.7)
Male	8	7.0	114.9	(49.5-226.3)	<b><u>Thyroid</u></b>				
Female	3	2.4	nc	(nc-nc)	Male	14	12.1	115.8	(63.2-194.3)
<b><u>Leukemia</u></b>					Female	34	38.2	89.1	(61.7-124.5)
Male	21	19.3	108.7	(67.3-166.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	15.3	104.4	(59.6-169.5)	Female	48	45.1	106.5	(78.5-141.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	16.1	93.1	(52.1-153.5)	Male	663	633.7	104.6	(96.8-112.9)
Female	4	5.6	nc	(nc-nc)	Female	699	690.2	101.3	(93.9-109.1)
<b><u>Lung and Bronchus</u></b>									
Male	98	85.2	115.0	(93.4-140.2)					
Female	113	95.6	118.1	(97.4-142.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	25.7	132.2	(91.6-184.8)	Male	19	16.8	113.3	(68.2-177.0)
Female	15	8.9	168.4	(94.2-277.8)	Female	14	13.0	107.3	(58.6-180.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.9	123.4	(45.1-268.7)	Male	5	4.9	101.5	(32.7-236.8)
Female	4	4.1	nc	(nc-nc)	Female	5	3.8	130.1	(41.9-303.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	17	14.8	115.2	(67.1-184.4)
Female	110	101.0	108.9	(89.5-131.3)	Female	9	12.2	74.1	(33.8-140.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	3.5	197.6	(79.2-407.1)	Male	8	12.0	66.8	(28.8-131.7)
<b><u>Colon / Rectum</u></b>					Female	9	5.1	176.8	(80.7-335.6)
Male	41	28.4	144.3	(103.5-195.8)	<b><u>Ovary</u></b>				
Female	31	26.9	115.1	(78.2-163.3)	Female	14	9.2	153.0	(83.6-256.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	7.0	114.0	(49.1-224.5)	Male	12	8.8	135.9	(70.1-237.4)
Female	2	1.7	nc	(nc-nc)	Female	6	8.6	69.4	(25.3-151.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	106	95.3	111.2	(91.1-134.5)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.0	99.4	(36.3-216.4)
Male	14	14.2	98.5	(53.8-165.2)	Female	0	3.4	nc	(nc-nc)
Female	1	8.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.2	185.3	(67.7-403.4)
Male	1	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	6	6.5	92.8	(33.9-202.0)
<b><u>Leukemia</u></b>					Female	20	18.9	105.9	(64.6-163.5)
Male	15	10.2	147.0	(82.2-242.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	7.2	194.8	(106.4-326.8)	Female	30	23.3	128.7	(86.8-183.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	8.8	148.4	(79.0-253.8)	Male	391	347.2	112.6	(101.7-124.3)
Female	8	2.7	291.3	(125.4-574.1)	Female	396	338.0	117.2	(105.9-129.3)
<b><u>Lung and Bronchus</u></b>									
Male	45	47.1	95.5	(69.7-127.8)					
Female	67	47.4	141.3	(109.5-179.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	10.0	89.9	(41.0-170.7)
Female	0	0.1	nc	(nc-nc)	Female	7	7.6	92.6	(37.1-190.7)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.3	nc	(nc-nc)					
Female	2	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	9.6	167.3	(95.5-271.6)	Male	8	6.5	122.3	(52.7-241.1)
Female	6	3.2	189.7	(69.3-412.9)	Female	6	4.5	133.7	(48.8-291.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	5	1.9	267.0	(86.0-623.0)
Female	3	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	10	5.8	172.6	(82.6-317.4)
Female	36	35.9	100.4	(70.3-139.0)	Female	5	4.3	117.2	(37.8-273.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	5	4.7	107.1	(34.5-249.9)
<b><u>Colon / Rectum</u></b>					Female	3	1.8	nc	(nc-nc)
Male	11	10.9	100.5	(50.1-179.9)	<b><u>Ovary</u></b>				
Female	10	9.6	104.0	(49.8-191.3)	Female	0	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	45	34.6	130.0	(94.8-173.9)
Female	2	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.3	nc	(nc-nc)
Male	3	5.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	6.4	nc	(nc-nc)
Male	5	3.9	127.2	(41.0-296.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.5	nc	(nc-nc)	Female	6	8.0	74.8	(27.3-162.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	161	131.5	122.4	(104.2-142.9)
Female	1	1.0	nc	(nc-nc)	Female	120	119.1	100.8	(83.6-120.5)
<b><u>Lung and Bronchus</u></b>									
Male	16	17.4	91.8	(52.4-149.0)					
Female	20	16.9	118.1	(72.1-182.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	28.2	170.2	(125.5-225.7)	Male	10	18.7	53.3	(25.5-98.1)
Female	13	10.1	128.4	(68.3-219.5)	Female	15	15.0	100.3	(56.1-165.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.6	nc	(nc-nc)	Male	7	5.4	129.3	(51.8-266.5)
Female	0	4.6	nc	(nc-nc)	Female	7	4.3	161.9	(64.9-333.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	18	16.6	108.2	(64.1-171.0)
Female	87	112.3	77.5	(62.0-95.5)	Female	17	13.7	123.9	(72.1-198.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.1	nc	(nc-nc)	Male	13	13.3	97.5	(51.8-166.7)
<b><u>Colon / Rectum</u></b>					Female	10	5.7	174.7	(83.6-321.4)
Male	25	31.8	78.7	(50.9-116.2)	<b><u>Ovary</u></b>				
Female	29	31.4	92.4	(61.9-132.8)	Female	9	10.2	87.9	(40.1-166.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	7.6	132.0	(63.2-242.7)	Male	11	9.6	114.0	(56.8-204.0)
Female	2	1.9	nc	(nc-nc)	Female	6	9.9	60.5	(22.1-131.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	2.5	280.4	(112.3-577.7)	Male	107	101.2	105.8	(86.7-127.8)
Female	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	6.7	194.7	(103.6-333.0)
Male	17	15.7	108.2	(63.0-173.3)	Female	1	3.9	nc	(nc-nc)
Female	11	8.9	124.0	(61.8-221.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	4.4	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	19	22.0	86.5	(52.0-135.1)
Male	12	11.6	103.9	(53.6-181.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	8.4	131.3	(65.5-235.0)	Female	25	25.3	99.0	(64.0-146.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	9.7	nc	(nc-nc)	Male	390	381.3	102.3	(92.4-112.9)
Female	2	3.1	nc	(nc-nc)	Female	358	380.4	94.1	(84.6-104.4)
<b><u>Lung and Bronchus</u></b>									
Male	49	50.6	96.8	(71.6-128.0)					
Female	60	51.9	115.6	(88.2-148.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	15.2	92.0	(50.2-154.3)	Male	4	9.9	nc	(nc-nc)
Female	8	5.7	141.0	(60.7-277.8)	Female	4	7.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	5	2.4	207.8	(67.0-484.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	14	8.7	160.9	(87.9-270.0)
Female	56	60.4	92.7	(70.0-120.4)	Female	5	7.5	66.4	(21.4-154.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.1	238.5	(76.9-556.5)	Male	8	6.9	115.3	(49.6-227.1)
<b><u>Colon / Rectum</u></b>					Female	2	3.1	nc	(nc-nc)
Male	10	16.7	59.8	(28.6-109.9)	<b><u>Ovary</u></b>				
Female	14	17.2	81.2	(44.4-136.3)	Female	7	5.5	127.0	(50.9-261.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	4.1	172.0	(68.9-354.4)	Male	6	5.2	116.2	(42.4-253.0)
Female	2	1.1	nc	(nc-nc)	Female	10	5.5	180.7	(86.5-332.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	60	54.2	110.7	(84.5-142.5)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.6	nc	(nc-nc)
Male	14	8.3	169.4	(92.5-284.3)	Female	1	2.2	nc	(nc-nc)
Female	8	4.9	164.8	(70.9-324.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.9	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	11.1	90.3	(43.2-166.0)
Male	5	6.0	83.9	(27.0-195.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	4.5	156.0	(62.5-321.5)	Female	12	13.7	87.6	(45.2-153.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.1	97.8	(31.5-228.2)	Male	228	202.1	112.8	(98.6-128.4)
Female	2	1.7	nc	(nc-nc)	Female	208	206.6	100.7	(87.5-115.3)
<b><u>Lung and Bronchus</u></b>									
Male	44	27.7	159.0	(115.5-213.4)					
Female	32	29.4	108.9	(74.5-153.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	7.9	152.9	(78.9-267.0)	Male	7	5.4	129.2	(51.8-266.3)
Female	4	2.7	nc	(nc-nc)	Female	5	4.3	116.8	(37.6-272.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.8	104.9	(33.8-244.8)
Female	36	33.9	106.1	(74.3-146.9)	Female	2	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	6	4.1	146.1	(53.3-317.9)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	10	9.1	110.0	(52.7-202.3)	<b><u>Ovary</u></b>				
Female	13	8.3	156.3	(83.1-267.2)	Female	1	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	39	31.3	124.5	(88.5-170.1)
Female	2	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	7	4.7	147.5	(59.1-304.0)	Female	0	1.0	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	6.6	197.2	(104.9-337.3)
Male	3	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.3	nc	(nc-nc)	Female	5	7.8	64.2	(20.7-149.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	133	112.0	118.7	(99.4-140.7)
Female	0	0.9	nc	(nc-nc)	Female	114	109.4	104.2	(85.9-125.2)
<b><u>Lung and Bronchus</u></b>									
Male	14	14.7	95.4	(52.1-160.1)					
Female	13	14.8	88.1	(46.8-150.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	7	11.2	62.5	(25.0-128.8)	Female	2	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	10	9.0	110.8	(53.1-203.8)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	32	33.2	96.3	(65.8-135.9)
Female	1	0.3	nc	(nc-nc)	Female	28	35.9	77.9	(51.8-112.6)
<b><u>Lung and Bronchus</u></b>									
Male	0	4.1	nc	(nc-nc)					
Female	8	4.6	175.3	(75.5-345.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	30.2	66.3	(40.5-102.4)	Male	34	19.0	179.4	(124.2-250.7)
Female	4	12.3	nc	(nc-nc)	Female	23	16.1	142.5	(90.3-213.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.5	91.6	(29.5-213.7)	Male	8	5.6	142.0	(61.1-279.8)
Female	6	5.1	117.6	(43.0-256.0)	Female	8	5.1	155.7	(67.1-306.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	12	16.9	71.0	(36.7-124.1)
Female	112	124.4	90.0	(74.1-108.3)	Female	12	15.9	75.5	(39.0-131.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.1	146.5	(53.5-318.8)	Male	10	13.3	75.4	(36.1-138.6)
<b><u>Colon / Rectum</u></b>					Female	5	6.6	76.2	(24.6-177.8)
Male	24	32.9	73.0	(46.8-108.7)	<b><u>Ovary</u></b>				
Female	44	37.4	117.7	(85.5-158.1)	Female	14	11.5	121.9	(66.6-204.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	7	10.1	69.1	(27.7-142.3)
Female	4	2.3	nc	(nc-nc)	Female	13	12.0	108.2	(57.5-185.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	122	103.2	118.2	(98.1-141.1)
Female	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	7.0	nc	(nc-nc)
Male	14	15.6	90.0	(49.2-151.0)	Female	4	4.7	nc	(nc-nc)
Female	12	10.1	118.8	(61.3-207.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.4	149.0	(48.0-347.7)
Male	1	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	7	6.9	101.2	(40.6-208.6)
<b><u>Leukemia</u></b>					Female	35	21.6	161.8	(112.7-225.0)
Male	11	11.9	92.4	(46.1-165.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	9.6	114.4	(57.0-204.6)	Female	31	28.2	110.1	(74.8-156.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	10.0	50.2	(16.2-117.2)	Male	351	390.9	89.8	(80.7-99.7)
Female	2	3.6	nc	(nc-nc)	Female	416	431.5	96.4	(87.4-106.1)
<b><u>Lung and Bronchus</u></b>									
Male	32	53.5	59.8	(40.9-84.5)					
Female	45	61.6	73.1	(53.3-97.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.9	78.3	(31.4-161.3)	Male	8	6.1	130.3	(56.1-256.8)
Female	2	3.1	nc	(nc-nc)	Female	1	4.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	45	37.8	118.9	(86.7-159.1)	Female	4	4.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.9	nc	(nc-nc)
Male	10	10.4	96.0	(46.0-176.6)	<b><u>Ovary</u></b>				
Female	7	9.6	72.9	(29.2-150.1)	Female	2	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	5	3.2	157.6	(50.8-367.8)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	31	36.4	85.2	(57.9-121.0)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	8	5.4	148.4	(63.9-292.4)	Female	1	1.2	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	7.2	nc	(nc-nc)
Male	5	3.6	137.9	(44.5-321.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.5	nc	(nc-nc)	Female	8	8.7	91.8	(39.5-180.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.4	146.4	(47.2-341.6)	Male	122	128.1	95.3	(79.1-113.7)
Female	0	1.0	nc	(nc-nc)	Female	105	123.1	85.3	(69.7-103.2)
<b><u>Lung and Bronchus</u></b>									
Male	17	16.7	101.6	(59.2-162.7)					
Female	11	16.6	66.1	(33.0-118.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.1	79.0	(34.0-155.7)	Male	7	6.5	107.2	(43.0-220.9)
Female	7	3.9	180.9	(72.5-372.8)	Female	2	5.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	41	39.7	103.3	(74.1-140.2)	Female	3	5.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.1	nc	(nc-nc)
Male	9	11.1	81.0	(36.9-153.7)	<b><u>Ovary</u></b>				
Female	15	11.7	128.2	(71.7-211.4)	Female	5	3.7	136.4	(43.9-318.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	30	36.1	83.0	(56.0-118.5)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.4	nc	(nc-nc)
Male	6	5.4	110.7	(40.4-241.0)	Female	0	1.5	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	7.0	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.0	nc	(nc-nc)	Female	11	9.1	120.6	(60.1-215.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	110	134.3	81.9	(67.3-98.7)
Female	0	1.1	nc	(nc-nc)	Female	121	137.4	88.1	(73.1-105.2)
<b><u>Lung and Bronchus</u></b>									
Male	16	18.3	87.2	(49.8-141.7)					
Female	15	19.7	76.0	(42.5-125.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	5.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.9	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	22.5	44.4	(21.2-81.6)
Female	0	0.2	nc	(nc-nc)	Female	10	18.8	53.1	(25.4-97.7)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.2	nc	(nc-nc)					
Female	1	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	4.2	188.6	(81.2-371.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	18	14.7	122.1	(72.3-193.0)
Female	0	0.1	nc	(nc-nc)	Female	8	12.1	65.9	(28.4-129.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.9	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.7	87.0	(28.0-203.1)	Male	12	3.5	345.7	(178.4-603.9)
Female	3	1.9	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	18	19.7	91.2	(54.0-144.1)	Female	1	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	3	6.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	5.8	119.8	(48.0-246.9)	Female	2	1.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	20.2	99.0	(60.4-152.9)
Female	2	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.3	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.2	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.4	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	71	73.2	97.0	(75.8-122.4)
Female	1	0.6	nc	(nc-nc)	Female	62	67.6	91.7	(70.3-117.5)
<b><u>Lung and Bronchus</u></b>									
Male	7	10.3	68.0	(27.2-140.1)					
Female	5	9.7	51.4	(16.6-119.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	10.1	69.5	(27.8-143.1)	Male	26	7.0	372.7	(243.4-546.1)
Female	3	3.4	nc	(nc-nc)	Female	18	5.3	341.9	(202.5-540.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	55	39.5	139.3	(104.9-181.3)	Female	5	4.7	107.1	(34.5-249.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	8	5.0	158.7	(68.3-312.6)
<b><u>Colon / Rectum</u></b>					Female	4	2.0	nc	(nc-nc)
Male	13	11.5	112.8	(60.0-192.8)	<b><u>Ovary</u></b>				
Female	11	10.4	105.8	(52.7-189.2)	Female	3	3.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	5	3.5	142.2	(45.8-331.9)
Female	4	0.6	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	47	38.4	122.4	(90.0-162.8)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.4	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.9	169.6	(54.7-395.9)
<b><u>Leukemia</u></b>					Female	9	8.0	112.1	(51.1-212.7)
Male	8	4.2	191.5	(82.5-377.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.8	nc	(nc-nc)	Female	11	9.0	122.9	(61.2-219.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	173	141.4	122.3	(104.8-142.0)
Female	0	1.0	nc	(nc-nc)	Female	154	131.5	117.2	(99.4-137.2)
<b><u>Lung and Bronchus</u></b>									
Male	15	18.6	80.6	(45.1-133.0)					
Female	12	17.7	67.7	(34.9-118.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	35.1	111.2	(79.1-152.0)	Male	21	22.9	91.6	(56.7-140.0)
Female	11	13.2	83.6	(41.7-149.6)	Female	21	19.1	109.9	(68.0-168.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	6.7	193.7	(103.0-331.3)	Male	7	6.7	104.7	(42.0-215.8)
Female	10	5.9	170.2	(81.5-313.1)	Female	6	5.6	106.9	(39.0-232.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	17	20.3	83.9	(48.8-134.3)
Female	159	146.1	108.8	(92.6-127.1)	Female	15	17.7	84.6	(47.3-139.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	5.2	nc	(nc-nc)	Male	16	16.2	98.8	(56.4-160.5)
<b><u>Colon / Rectum</u></b>					Female	10	7.4	135.2	(64.7-248.7)
Male	47	39.1	120.2	(88.3-159.9)	<b><u>Ovary</u></b>				
Female	31	40.4	76.8	(52.2-109.0)	Female	21	13.2	158.7	(98.2-242.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	9.3	118.0	(58.8-211.1)	Male	13	11.9	109.0	(58.0-186.4)
Female	3	2.5	nc	(nc-nc)	Female	7	12.8	54.6	(21.9-112.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	121	123.2	98.2	(81.5-117.3)
Female	3	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	8.2	121.5	(58.2-223.4)
Male	16	19.1	83.7	(47.8-135.9)	Female	2	5.1	nc	(nc-nc)
Female	9	11.6	77.8	(35.5-147.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	4.6	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	5	1.8	282.4	(91.0-658.9)	Male	15	8.9	169.1	(94.6-278.9)
<b><u>Leukemia</u></b>					Female	24	27.8	86.4	(55.4-128.6)
Male	12	14.1	85.1	(43.9-148.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	10.7	84.3	(38.5-160.1)	Female	29	32.9	88.2	(59.1-126.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	11.9	nc	(nc-nc)	Male	477	466.5	102.2	(93.3-111.9)
Female	3	4.0	nc	(nc-nc)	Female	492	492.5	99.9	(91.3-109.1)
<b><u>Lung and Bronchus</u></b>									
Male	52	63.0	82.5	(61.6-108.2)					
Female	73	68.4	106.7	(83.6-134.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	35.5	112.6	(80.4-153.3)	Male	34	22.0	154.6	(107.1-216.1)
Female	10	13.4	74.7	(35.8-137.4)	Female	18	17.3	104.2	(61.7-164.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.2	128.7	(55.4-253.7)	Male	8	6.5	122.2	(52.6-240.8)
Female	9	5.5	163.9	(74.8-311.2)	Female	5	5.6	89.5	(28.9-209.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	26	19.6	132.7	(86.7-194.5)
Female	153	134.8	113.5	(96.2-133.0)	Female	16	17.2	93.0	(53.1-151.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.4	nc	(nc-nc)	Male	13	15.2	85.4	(45.4-146.1)
<b><u>Colon / Rectum</u></b>					Female	6	7.1	84.8	(31.0-184.6)
Male	29	38.5	75.2	(50.4-108.1)	<b><u>Ovary</u></b>				
Female	33	41.1	80.2	(55.2-112.7)	Female	12	12.4	97.1	(50.1-169.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	9.1	77.2	(30.9-159.1)	Male	11	11.8	92.8	(46.3-166.1)
Female	4	2.5	nc	(nc-nc)	Female	17	13.2	128.5	(74.8-205.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	156	117.6	132.7	(112.7-155.2)
Female	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	8.1	85.9	(34.4-177.1)
Male	14	17.9	78.0	(42.6-130.9)	Female	2	5.2	nc	(nc-nc)
Female	10	10.9	91.7	(43.9-168.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.4	nc	(nc-nc)
Male	5	5.0	100.9	(32.5-235.4)	<b><u>Thyroid</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	9	7.8	115.5	(52.7-219.3)
<b><u>Leukemia</u></b>					Female	39	22.8	171.0	(121.6-233.7)
Male	7	13.8	50.6	(20.3-104.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	10.5	142.4	(79.6-234.8)	Female	29	30.2	96.1	(64.3-138.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	11.4	44.0	(14.2-102.6)	Male	455	451.5	100.8	(91.7-110.5)
Female	1	3.9	nc	(nc-nc)	Female	465	466.7	99.6	(90.8-109.1)
<b><u>Lung and Bronchus</u></b>									
Male	41	62.4	65.7	(47.2-89.2)					
Female	40	65.9	60.7	(43.3-82.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	5	3.6	139.8	(45.1-326.3)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	110	96.8	113.6	(93.4-136.9)	Male	33	61.9	53.3	(36.7-74.9)
Female	38	39.7	95.6	(67.7-131.3)	Female	23	53.8	42.8	(27.1-64.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	18.3	87.5	(50.0-142.1)	Male	20	18.0	111.2	(67.9-171.7)
Female	21	16.9	124.5	(77.0-190.3)	Female	14	16.5	84.6	(46.2-142.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	51	55.0	92.7	(69.0-121.9)
Female	339	392.8	86.3	(77.4-96.0)	Female	36	51.4	70.0	(49.0-96.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	24	13.7	174.8	(111.9-260.0)	Male	59	42.2	139.9	(106.5-180.5)
<b><u>Colon / Rectum</u></b>					Female	30	20.9	143.4	(96.7-204.7)
Male	119	105.3	113.0	(93.6-135.2)	<b><u>Ovary</u></b>				
Female	107	120.9	88.5	(72.5-106.9)	Female	37	36.7	100.8	(71.0-139.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	34	24.9	136.3	(94.4-190.5)	Male	36	32.4	111.1	(77.8-153.8)
Female	9	7.5	119.7	(54.6-227.3)	Female	63	39.1	161.1	(123.8-206.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	9	8.2	110.3	(50.3-209.5)	Male	379	326.2	116.2	(104.8-128.5)
Female	4	7.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	37	22.3	165.8	(116.7-228.5)
Male	71	50.4	140.9	(110.1-177.8)	Female	27	15.4	175.1	(115.4-254.8)
Female	46	32.4	142.0	(104.0-189.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	14.3	56.0	(24.1-110.3)
Male	21	13.7	153.1	(94.8-234.1)	<b><u>Thyroid</u></b>				
Female	14	4.8	288.9	(157.8-484.7)	Male	20	23.5	85.1	(51.9-131.4)
<b><u>Leukemia</u></b>					Female	74	73.5	100.6	(79.0-126.4)
Male	37	39.0	95.0	(66.9-130.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	23	31.8	72.3	(45.8-108.5)	Female	93	88.3	105.4	(85.0-129.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	69	31.3	220.3	(171.4-278.9)	Male	1477	1258.4	117.4	(111.5-123.5)
Female	11	11.5	95.7	(47.7-171.2)	Female	1365	1389.3	98.2	(93.1-103.6)
<b><u>Lung and Bronchus</u></b>									
Male	244	171.9	141.9	(124.7-160.9)					
Female	199	197.6	100.7	(87.2-115.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	14.0	78.7	(39.3-140.9)
Female	0	0.1	nc	(nc-nc)	Female	12	13.7	87.6	(45.2-153.0)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	10	7.7	129.4	(62.0-238.0)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.4	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	9.3	54.0	(17.4-126.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	18	32.1	56.1	(33.2-88.7)
Female	0	0.2	nc	(nc-nc)	Female	23	26.1	88.1	(55.8-132.2)
<b><u>Lung and Bronchus</u></b>									
Male	0	4.5	nc	(nc-nc)					
Female	2	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.2	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	17.1	64.5	(32.1-115.3)
Female	0	0.1	nc	(nc-nc)	Female	10	13.8	72.3	(34.6-133.0)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.2	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;